Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
Lonza has scored a contract manufacturing agreement from Osiris
Therapeutics for its investigational adult stem cell therapy is
building a new facility to support future business activities in
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
While Lonza's biopharmaceutical business has taken off, tough
competition from cheap Asian competitors is eating away at its
exclusive synthesis business - meanwhile, the whole business is
being hit by rising raw material and...
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.